**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 73565

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

***Bifidobacterium infantis* regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease**

Zhou LY *et al*. Regulation of PD-1/PD-L1 pathway in IBD

Lin-Yan Zhou, Ying Xie, Yan Li

**Lin-Yan Zhou, Ying Xie, Yan Li,** Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Author contributions:** Zhou LY obtained funding, processed the samples, analyzed the raw data, and wrote manuscript; Xie Y processed the samples, obtained and managed data; Li Y conceived the study protocol, critically revised the manuscript, and approved the final version.

**Supported by** theDoctoral Start-up Foundation of Liaoning Province, No. 2021-BS-114.

**Corresponding author: Yan Li, PhD, Chief Doctor, Professor,** Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Road, Heping District, Shenyang 110004, Liaoning Province, China. liy@sj-hospital.org

**Received:** December 6, 2021

**Revised:** January 12, 2022

**Accepted: June 16, 2022**

**Published online:**

**Abstract**

BACKGROUND

Inflammatory bowel disease (IBD) is caused by an abnormal immune response. Programmed cell death 1 (PD-1) is an immunostimulatory molecule, which interacts with PD ligand (PD-L1) playing a prime important role among autoimmune diseases. *Bifidobacterium infantis* (*B. infantis*) can promote the differentiation of CD (cluster of differentiation) 4+ T cells into regulatory T cells (Tregs). Tregs participate in the development of IBD and may be related to disease activity. *B. infantis* amplify the expression level of PD-1, PD-L1 and Tregs’ nuclear transcription factor forkhead box protein 3 (Foxp3). But the mechanism of *B. infantis* on PD-1/PD-L1 signaling remains unclear.

AIM

To explore the mechanism of *B. infantis* regulating the immune response in IBD.

METHODS

Forty-eight-week-old BALB/c mice were randomly divided into five groups: The control group, dextran sulphate sodium (DSS) model group, DSS + *B. infantis* group, DSS + *B. infantis* + anti-PD-L1 group, and DSS + anti-PD-L1 group. The control group mice were given drinking water freely, the other four groups were given drinking water containing 5% DSS freely. The control group, DSS model group, and DSS + anti-PD-L1 group were given normal saline (NS) 400 μL daily by gastric lavage, and the DSS + *B. infantis* group and DSS + *B. infantis* + anti-PD-L1 group were given NS and 1 × 109 colony-forming unit of *B. infantis* daily by gastric lavage. The DSS + *B. infantis* + anti-PD-L1 group and DSS + anti-PD-L1 group were given 200 μg of PD-L1 blocker intraperitoneally at days 0, 3, 5, and 7; the control group, DSS + anti-PD-L1 group, and DSS + *B. infantis* group were given an intraperitoneal injection of an equal volume of phosphate buffered saline (PBS). Changes in PD-L1, PD-1, Foxp3, interleukin (IL)-10, and transforming growth factor β (TGF-β) 1 protein and gene expression were observed. Flow cytometry was used to observe changes in CD4+, CD25+, Foxp3+ cell numbers in the blood and spleen.

RESULTS

Compared to the control group, the expression of PD-1, Foxp3, IL-10, and TGF-β1 was significantly decreased in the intestinal tract of the DSS mice (*P* < 0.05). Compared to the control group, the proportion of CD4+, CD25+, Foxp3+ cells in spleen and blood of DSS group was visibly katabatic (*P* < 0.05). *B. infantis* upgraded the express of PD-L1, PD-1, Foxp3, IL-10, and TGF-β1 (*P* < 0.05) and increased the proportion of CD4+, CD25+, Foxp3+ cells both in spleen and blood (*P* < 0.05). After blocking PD-L1, the increase in Foxp3, IL-10, and TGF-β1 protein and gene by *B. infantis* was inhibited (*P* < 0.05), and the proliferation of CD4+, CD25+, Foxp3+ cells in the spleen and blood was also inhibited (*P* < 0.05). After blocking PD-L1, the messenger ribonucleic acid and protein expression of PD-1 were invariant.

CONCLUSION

It is potential that *B. infantis* boost the proliferation of CD4+, CD25+, Foxp3+ T cells in both spleen and blood, as well as the expression of Foxp3 in the intestinal tract by activating the PD-1/PD-L1 pathway.

**Key Words:** *Bifidobacterium infantis*; Enteritis; Programmed cell death ligand; T-Lymphocytes

Zhou LY, Xie Y, Li Y. *Bifidobacterium infantis* regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease. *World J Gastroenterol* 2022; In press

**Core Tip:** *Bifidobacterium infantis* (*B. infantis*) can be used as a therapeutic agent to treat inflammatory bowel disease. It regulates the intestinal microbiota, alleviates inflammation, and regulates the immune response.We found that *B. infantis* increases the expression of forkhead box protein 3 (Foxp3) and the proliferation of Foxp3+ T cells, and activates the programmed cell death 1 (PD-1)/ PD ligand 1 pathway.

**INTRODUCTION**

Inflammatory bowel disease (IBD) results from the aberrant immune responses or the disruption of immune tolerance to intestinal antigens. Several factors, including the immune system, infections, and genetic and environmental factors, may remarkably contribute to the development of IBD[1-4]. To maintain immune tolerance to the intestinal environment, the intestinal immune system monitors changes in the bacterial microbiota and the expression of antigens on the surface of the intestinal mucosa[5,6]. Antigen-presenting cells, including dendritic cells and intestinal epithelial cells, present intestinal antigens to CD4+ T cells and induce their differentiation into regulatory T cells (Tregs), which maintain tolerance to the intestinal microbiota. Hyperactive T cell responses to the intestinal microbiota contribute to the inflammatory response observed in IBD[7].

Programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1), belong to the CD28/B7 superfamily, which primarily functions in T cell-mediated immune responses and is closely related to several diseases and disease states, including autoimmune diseases, tumors, chronic viral infections, and chronic inflammation[8-10]. The role of the PD-1/PD-L1 signaling pathway in glomerulonephritis, systemic lupus erythematosus, rheumatoid arthritis, dilated cardiomyopathy, autoimmune diabetes, and other autoimmune diseases has been widely studied[11,12]; however, few studies have examined the role of the PD-1/PD-L1 signaling pathway in IBD[13].

Tregs are a subpopulation of T lymphocytes with immunoregulatory functions[14]. They can inhibit the activation and proliferation of autoreactive T cells by secreting cytokines such as interleukin (IL)-10 and transforming growth factor β (TGF-β), downregulating the function of auxiliary T cells, and maintaining intestinal homeostasis and immune tolerance[15,16]. Tregs are divided into two categories: Natural Tregs (nTregs) and induced Tregs (iTregs). The nTregs mature in the thymus and are positive for CD4, CD25, and Foxp3. The iTregs are induced by specific antigen stimulation of CD4+ T cells in the presence of IL-2 and TGF-β1, in the intestine, spleen, and other peripheral sites[17]. Animal studies have shown that injecting T cells with no CD4 and Tregs expressing CD25 into T cell-deficient mice can induce the development of autoimmune colitis, whereas the injection of T cells expressing CD4with that of CD25+ Tregs can inhibit colitis development. These results suggest that CD4+ and CD25+ Tregs are vital for the inhibition of the intestinal immune response[18]. Maul *et al*[19] found that the percentage of Tregs in the peripheral blood of patients with IBD decreased in the active phase and increased in the remission phase of the disease; however, the number of Tregs in the intestinal epithelium increased in the active phase of the disease but was still significantly lower than that observed in patients with diverticulitis. This suggests a role of Tregs in IBD development.

The adoptive transfer of immature CD4+ T cells into wild-type rag-/- mice and PD-L1-/-rag-/- mice significantly decreases the number of Tregs in PD-L1-/-rag-/- mice, suggesting a dominant role of PD-L1 in Treg differentiation[20]. PD-L1 can enhance Treg function and promote the production of IL-10 by Tregs[21]. Treg differentiation depends on the PD-L1 signaling pathway. Higher levels of PD-L1 expression in hepatodendritic cells result in greater induction of Tregs which maintain the tolerance toward transplanted organs.

We have previously found that *Bifidobacterium infantis* (*B. infantis*)can alleviate intestinal epithelial injury and maintain intestinal immune tolerancein a mouse model of IBD and may have therapeutic implications for the immunological injuries observed in IBD**.** *Bifidobacterium infantis* notablyincreased the expression levels of PD-L1 and PD-1 in the intestine and promoted the expression of nuclear transcription factors and of anti-inflammatory factors (IL-10 and TGF-β1) in Tregs[22,23]. Therefore, this study aimed to explore the mechanism of action of *B. infantis* in the PD-1/PD-L1 signaling pathway and the differentiation and function of Tregs.

**MATERIALS AND METHODS**

***Reagents and antibodies***

Dextran sulfate sodium (DSS; molecular weight 36000-50000) was purchased from MP Biomedicals (Irvine, CA, United States). *B. infantis* freeze-dried powder, containing 1.6 × 1011 colony-forming units (CFU)/g, was provided by Shandong Kexing Biological Products Co., Ltd. (Batch No. 2017012, Shandong Province, China). Invivomab anti-mouse PD-L1 was purchased from BIOX Cell (Lebanon, NH, United States). BALB/c mice were purchased from Huafukang Biotechnology (Beijing, China). Allophycocyanin (APC) rat anti-mouse Cd4, Bb515 rat anti-mouse, P-phycoerythrin (PE) rat anti-mouse Foxp3, and a transcription factor buffer set were purchased from BD Biosciences (Franklin Lakes, NJ, United States). Antibodies against PD-L1, PD-1, and Foxp3 were purchased from Proteintech Group (Rosemont, IL, United States). Antibodies against IL-10 and TGF-β1 were purchased from Abcam (Cambridge, United Kingdom). Real-time quantitative PCR was performed using the following reagents: TRIzol (Invitrogen, Thermo Fisher, Waltham, MA, United States), PrimescriptTM RT Regent kit with gDNA eraser, quick response training (qRT) PCR kit SYBR® premier ex taqTM II (Tli RNaseH Plus, Takara, Japan), and the specific primers (Biotechnology Co., Ltd., China).

***Animals***

Forty-eight-week-old BALB/c mice, male and female, weighing 20 g ± 2 g, were raised under pathogen-free conditions in the standalone animal experimental center affiliated with the Shengjing Hospital of China Medical University. The mice were kept at 20 °C-26 °C and in an atmosphere with a relative humidity of 40%-70%, with a 12 h light/dark cycle. Sterilized water and standard feed were provided for free consumption by the animals. The experimental protocol was approved by the ethics committee of the hospital (No. 2017PS353K). The operators ensured that suitable measures were taken to reduce malaise and injury to the animals during experiments.

***Experimental grouping and modeling***

Forty mice were randomly divided into five groups: Control, DSS, DSS + *B. infantis*, DSS + *B. infantis* + anti-PD-L1, and DSS + anti-PD-L1.Mice in the control group were given free access drinking water for 7 d. The other four groups were administered sterilized water containing 5% DSS for 7 d. The drinking. Drinking water was changed daily.The control, DSS, and DSS + anti-PD-L1 groups were administered 400 μL normal saline (NS) *via* gavage daily, and the DSS + *B. infantis* and DSS + *B. infantis* + anti-PD-L1 groups were administered 400 μL NS *via* gavage and *B. infantis* (1 × 109 CFU) daily. The DSS + *B. infantis* + anti-PD-L1 and DSS + anti-PD-L1 groups were administered an intraperitoneal injection of PD-L1 blocker (200 μg), and the control, DSS model, and DSS + *B. infantis* groups were intraperitoneally injected with phosphate-buffered phosphate buffered saline (PBS) on days 0, 3, 5, and 7.

***Specimen collection***

**General characteristics of the mice:** During the experimental period, temperament, reactivity, activity, hair color, weight, eating, and defecation of each mouse were observed seriatim and recorded in detail daily.

**Peripheral blood collection:** On day 8, all animals were anesthetized *via* isoflurane inhalation, and the beards were removed. Blood was collected through retro-orbital bleeding and placed in blood collection vessels containing EDTA. The blood and EDTA were mixed and stored on ice.

**Extraction of single cells from mouse spleen:** After blood collection, the sacrificed mice were dissected along the midline, and the spleen was fully exposed. After blunt dissection, the spleen was removed, placed in PBS, and transported on ice. The spleen was then transferred to a glass dish containing RPMI 1640 medium and mashed with ground glass. The cells were then transferred to a centrifuge tube and centrifuged at 1200 rpm for 5 min, and the supernatant was discarded. Next, 2 mL of RBC lysate was added to each sample. PBS (3 mL) was added to dilute and stop the lysis, and the samples were centrifuged again at 400 × *g* for 5 min at 4 °C. The supernatant was discarded and 3 mL of PBS was added. The cells were filtered and centrifuged for 10 min. The supernatant was discarded, and PBS was added to obtain a single-cell suspension. All the procedures were performed at 4 °C to ensure cell viability.

**Acquisition of mouse colon:** After splenectomy, the colon was exposed and the colon from the blind part to the anus was removed, washed with pre-cooled NS, and divided into four parts. The samples were then transferred to a -80 °C ultra-low-temperature refrigerator in liquid nitrogen for long-term preservation.

***Detection of CD4+, CD25+, Foxp3+ T cells by flow cytometry***

**Spleen:** Splenic CD4+, CD25+, and Foxp3+ T cells were detected using flow cytometry. The prepared single-cell spleen suspension (100 μL) was aliquoted into labeled flow tubes. Anti-CD4+ and anti-CD25+ antibodies were then added to the tubes and the tubes were incubated at 4 °C in the dark for 30 min. Next, 1 mL of 1X fix/perm working solution was added to each sample and the samples were incubated at 4 °C in the dark for 40 min to permeabilize the nucleus. Anti-Foxp3 antibody was then added and the resulting solution was incubated at 4 °C in the dark for 40 min. Excess antibodies were removed, and the samples were run on a flow cytometer (FACSCalibur, BD Bioscience).

**Peripheral blood:** After RBC lysis, flow cytometry was performed on the peripheral blood samples using the protocol described above.

***Western blotting***

Total protein was extracted from the colon, and the protein concentration was determined. The samples were subjected to electrophoresis at 60 V. After marker separation, the voltage was adjusted to 80 V. After 30 min, the voltage was adjusted to 100 V. Electrophoresis was terminated when the target protein with the lowest molecular weight reached the end of the gel. A voltage of 100 V was used to transfer proteins to the membrane. Proteins with a molecular weight < 25 kDa were transferred for 25 min, and proteins weighing 26-70 kDa were transferred for 70 min. The membrane was blocked with 2.5% bovine serum albumin (BSA) at room temperature for 1.5 h. Primary antibodies against PD-L1 (1:750), PD-1 (1:500), Foxp3 (1:1000), IL-10 (1:800), TGF-β1 (1:500), and GAPDH (1:10000) were added and the membrane was incubated at 4 °C overnight. Then, goat anti-rabbit IgG secondary antibody labeled with horseradish peroxidase was added to the membrane, followed by incubation at room temperature for 1.5 h. In a dark room, a chemiluminescence imaging analysis system was used to visualize the membranes. GelPro software was used to analyze the images and to perform quantitative analysis using the following formula: Protein content = grey value of the target protein of the sample/grey value of the same sample.

***Real-time qPCR***

***Real time qPCR***

The experiment consists of 5 steps: (1) Ribonucleic acid (RNA) purification: DSS can reduce the purity of RNA, so extra purification of the colon RNA was necessary. RNA purification was performed as follows: 30 µL lithium chloride (8 mol/L) + 270 µL ddH2O was added to 10 µL RNA and placed on ice for 2 h. The samples were then centrifuged at 14000 × g for 30 min. The supernatant was then discarded, and the RNA was dissolved in 90 µL ddH2O. Next, 10 µL sodium acetate (3 mol/L) + 200 µL anhydrous ethanol was added to the RNA and incubated at -20 °C for 30 min to precipitate the RNA. The samples were then centrifuged at 14000 × g for 30 min at 4 °C. The supernatant was then discarded, 500 µL 75% ethanol was added, and the samples were gently blown with a pipette to clean the RNA. Next, the samples were centrifuged at 800 × g for 10 min at 4 °C. The supernatant was discarded, and the RNA was dissolved with 10 µL ddH2O. Finally, the samples were transferred to -80 °C on ice for preservation; (2) detection of RNA concentration: The ratio of A260/A280 was eligible for all of the samples, which indicates that the purity of the RNA was high and suitable for further experiments; (3) preparation of cDNA by RNA reverse transcription: The gDNA was removed, and the specimens were heated to 42 °C for 2 min. For reverse transcription, the reaction solution was prepared according to Table 1. The samples were heated at 37 °C for 15 min and 85 °C for 5 s. The reaction was then stopped and cooled down to 4 °C; (4) concentration and purity of cDNA: After zero adjustment, 1 μL of the cDNA sample to be tested was dropped onto the detection probe to determine the concentration and purity. The probe was washed with ddH2O between the evaluation of the two samples; and (5) qRT-PCR: qRT-PCR was carried out as follows: PCR amplification reaction, denaturation at 95 °C for 5 min, PCR reaction at 95 °C for 10 s, and 60 °C for 30 s for 45 cycles.

***Statistical analysis***

Data are presented as mean ± SD. Differences among the groups were analyzed using the analysis of variance. SPSS (version 23.0; IBM, Armonk, NY, United States) and GraphPad 7.0 (Software, CA, United States) statistical software were used to perform statistical analyses. Two-tailed *P* values were calculated, and statistical significance was set as *P* < 0.05.

**RESULTS**

***The effect of B. infantis on the expression of PD-1 after PD-L1 blockade***

**Western blot results:** Compared to the DSS + *B. infantis* group, PD-1 protein in the DSS + *B. infantis* + anti-PD-L1 group decreased, but the difference was not statistically significant (*P* = 0.07). Compared to DSS model group, the expression of PD-1 was no significant distinction in DSS + anti-PD-L1 group (*P* = 0.62) (Figure 1A-C).

**qRT-PCR results:** In contrast to control group, PD-1 messenger ribonucleic acid (mRNA) in DSS group decreased significantly (*P* < 0.05). In constrast to DSS group, the expression of DSS + *B. infantis* group increased, but the difference was not statistically significant (*P* = 0.36). Compared to the *B. infantis* group, PD-1 RNA decreased significantly in the DSS + *B. infantis* + anti-PD-L1 group (*P* < 0.05) (Figure 1A-C).

***Effect of B. infantis on Tregs and Foxp3 expression after PD-L1 blockade***

**Western blot results:** Compared to the DSS + *B. infantis* group, Foxp3 protein decreased in DSS + *B. infantis* + anti-PD-L1 group, and the difference was statistically significant (*P* < 0.05). There was no significant difference in Foxp3 protein expression between the DSS model group and DSS + anti-PD-L1 group (*P* = 0.99) (Figure 1D-F).

**RT-qPCR results:** In contrast to control group, Foxp3 mRNA in DSS model group decreased significantly (*P* < 0.05); Foxp3 mRNA in DSS + *B. infantis* group was significantly higher than that in DSS model group (*P* < 0.05). Compared to the *B. infantis* group, the expression of Foxp3 mRNA decreased significantly in the DSS + *B. infantis* + anti-PD-L1 group (*P* < 0.05). In comparison with DSS model group, Foxp3 mRNA in DSS + anti-PD-L1 group was also visible distinction (*P* < 0.05) (Figure 1D-F).

***Flow cytometry results***

**Flow cytometry of peripheral blood:** Compared to control group, the proportion of peripheral CD4+, CD25+, Foxp3+ cells decreased visibly (*P* < 0.05) of DSS group and increased visibly in the blood of the DSS + *B. infantis* group (*P* < 0.05). Compared to the DSS + *B. infantis* group, the proportion of CD4+, CD25+, Foxp3+ cells in the peripheral blood of DSS + *B. infantis* + anti-PD-L1 group was significantly lower (*P* < 0.05). The proportion of CD4+, CD25+, Foxp3+ cells in the blood of the DSS + anti-PD-L1 group was also distinctly lower compared to the DSS group (*P* < 0.05) (Figure 2).

**Flow cytometry of splenocytes:** The ratio of splenic CD4+, CD25+, Foxp3+ cells in DSS model group was significantly lower (*P* < 0.05), comparing to control group. The ratio of CD4+, CD25+, Foxp3+ cells in the DSS + *B. infantis* group was significantly higher than that in the DSS model group (*P* < 0.05). Compared to the DSS + *B. infantis* group, the proportion of CD4+, CD25+, Foxp3+ cells in the DSS + *B. infantis* + anti-PD-L1 group decreased significantly (*P* < 0.05). The proportion of CD4+, CD25+, Foxp3+ cells in the DSS + anti-PD-L1 group also decreased significantly compared to the DSS group (*P* < 0.05) (Figure 3).

***The effect of B. infantis on the expression of IL-10 and TGF-β1 after PD-L1 blockade***

**Western blot results:** The expression of IL-10 and TGF-β1 protein in the DSS + *B. infantis* group was lower than that in DSS + *B. infantis* + anti-PD-L1 group (*P* < 0.05). Compared to the DSS model group, there was no apparent distinction in the express of IL-10 (*P* = 0.99) or TGF-β1 in the DSS + anti-PD-L1 group (*P* < 0.05) (Figure 4).

**Real time PCR results:** In comparison with control group, mRNA of IL-10 and TGF-β1 in the DSS model group decreased (*P* < 0.05), and mRNA of IL-10 and TGF-β1 in the DSS + *B. infantis* group increased clearly (*P* < 0.05). IL-10 and TGF-β1 mRNA expression in DSS + *B. infantis* + anti-PD-L1 group decreased clearly (*P* < 0.05) contrsating to DSS + *B. infantis* group. Compared to the DSS model group, IL-10 and TGF-β1 mRNA in DSS + anti-PD-L1 group were also statistically distinction (*P* < 0.05) (Figure 4).

**DISCUSSION**

The specific pathogenesis of IBD remains unclear; however, abnormal inflammatory responses and continuous inflammatory damage to the intestine are recognized as the basic mechanisms of IBD pathogenesis[24,25]. Intestinal immunity is a complex and interactive process, involving several immune factors such as intestinal mucosal immunity, T cells, cytokines, and intestinal microecology[26]. The intestinal mucosal immune system is responsible for monitoring the intestinal microbiota and surface antigens[27], presenting antigens to CD4+ T cells, promoting the interaction between PD-1 and PD-L1, establishing immune tolerance, and preventing the occurrence of autoimmunity. Several inflammatory mediators including interferon γ, tumor necrosis factor α, IL-10, and other cytokines, are involved in the pathogenesis of DSS colitis, suggesting that inflammatory immune responses play a critical role in the pathogenesis of IBD[28-30].

A recently discovered immunostimulatory molecule, PD-1 interacts with its ligand PD-L1 to regulate T cell-mediated immunity and induce immune tolerance, thereby playing a critical role in autoimmune diseases (such as IBD), tumor immunity, and the acceptance of transplanted organs. Studies have shown that PD-1 knockout results in autoimmune diseases in animal models[31-33]. Activation of the PD-1/PD-L1 signaling pathway can induce the differentiation of Tregs[34] and the release of cytokines, such as IL-10 and TGF-β1, to inhibit the activation and proliferation of reactive T cells, thus maintaining intestinal immune tolerance. Additionally, the inhibition of the PD-1/PD-L1 pathway may reduce the proportion of Tregs[35]. These findings indicate that PD-1/PD-L1 signaling plays a critical role in immune tolerance[36]. In this study, we found that PD-L1 inhibition did not alter the PD-1 protein and mRNA levels in the intestine of DSS-induced mice, suggesting that PD-L1 did not affect the transcription or translation of PD-1 in the intestine of the IBD mouse model. However, although the expression of PD-1 mRNA in the intestinal tracts of DSS mice significantly decreased, the expression of PD-1 protein did not change after *B. infantis* administration. We, therefore, speculate that PD-L1 inhibition may indirectly inhibit the *B. infantis*-induced PD-1 gene transcription, but not the post-transcriptional modification and translation of PD-1 protein. This transcriptional inhibition of PD-1 may be due to a negative feedback mechanism caused by the high PD-1 protein levels. Further studies are needed to determine how PD-L1 inhibition suppresses the transcription and translation of PD-1 and the underlying mechanism of action of the effect of *B. infantis* on PD-1 after PD-L1 inhibition.

*B.* *infantis* can be used to treat IBD by regulating the intestinal microbiota, alleviating inflammation, and regulating the immune response. *B.* *infantis* can reduce the intestinal wall permeability, edema, and neutrophil infiltration in IBD mice, and alleviate intestinal inflammatory responses[37]. We have previously shown that a combined administration of *B. infantis* with *Clostridium butyricum* increases the abundance of probiotic bacteria (such as members of the genera *Bifidobacterium* and *Lactobacillus)* in the intestinal microbiota of patients with IBD, reduces the prevalence of enterococci, improves clinical symptoms, and promotes the healing of colonic mucosa[38]. *B. infantis* also plays an important role in immune regulation by promoting the proliferation of Tregs[39] and increasing the expression of IL-10 and TGF-β1. *In vivo* and *in vitro* experiments have revealed that *B. infantis* can significantly accelerate the differentiation of CD4+ T cells into Tregs by inducing the maturation of resistant dendritic cells and further inhibiting the inflammatory response induced by reactive T cell activation. Furthermore, we have previously revealed that, compared to the observations in normal mice, the number of CD4+, CD25+, and Foxp3+ T cells in the blood and spleen of DSS mice and the expression of Foxp3 mRNA in their intestines showed a decrease, suggesting that the differentiation and proliferation of Tregs may be correlated to the pathogenesis of IBD[40]. The number of Tregs in the colon was reported to be related to the intestinal microbiota. Treg populations in the colons of sterile mice are significantly low; however, feeding sterile mice with feces collected from specific pathogen-free mice significantly increases the number of Tregs in the colon[41], indicating that Treg population is dependent on the intestinal microbiota. In patients with IBD, the proportion of normal intestinal bacteria decreases, resulting in intestinal microbiota-associated disorders[42]. Therefore, improving the composition of the intestinal microbiota can help increase the number of Tregs; however, further studies are needed for the elucidation of the underlying mechanism. In the present study, we found that *B. infantis* promotes the proliferation of CD4+, CD25+, and Foxp3+ T cells in the blood and spleen, as well as the expression of Foxp3 mRNA in the intestine. PD-L1 inhibition significantly reduced the numbers of CD4+, CD25+, and Foxp3+ T cells in the blood and spleen, and decreased the expression of Foxp3 protein and mRNA in the intestine. Therefore, *B. infantis* promotes Treg proliferation by activating the PD-L1/PD-1 pathway.

In addition, our results indicate that *B. infantis* promoted the mRNA expression of IL-10 and TGF-β1 in the mouse intestine. PD-L1 inhibition significantly reduced the protein and mRNA expression levels of IL-10 and TGF-β1 in the intestine. These results further indicate that *B. infantis* affected IL-10 and TGF-β1 expression through the PD-1/PD-L1 pathway. Notably, Tregs mainly secrete TGF-β1 and IL-10 to inhibit inflammatory responses. Further studies are needed to confirm the immunosuppressive effects of *B. infantis* in patients with IBD. Additionally, Francisco *et al*[20] found that PD-L1 can downregulate Protein kinase B (Akt), mammalian target of rapamycin (mTOR), and extracellular regulated protein kinases (ERK2), while upregulating phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression in Tregs; however, whether *B. infantis* can accelerate the differentiation and proliferation of Tregs by activating the PD-1/PD-L1 pathway and regulating Akt, mTOR, or PTEN expression requires further investigation.

**CONCLUSION**

In conclusion, *B. infantis* may accelerate the proliferation of CD4+, CD25+, and Foxp3+ T cells in the spleen and peripheral blood, and the expression of Foxp3 in the intestine by activating the PD-1/PD-L1 signaling pathway. It can also promote the expression of IL-10 and TGF-β1 to reduce the intestinal inflammatory response, which has a therapeutic effect on IBD mice. We aim to further investigate the role of the PD-1/PD-L1 pathway in IBD and the possible therapeutic effect of *B. infantis* on patients with IBD in future studies.

**ARTICLE HIGHLIGHTS**

***Research background***

The immune-inflammatory response plays an important role in the pathogenesis and development of inflammatory bowel disease (IBD). *Bifidobacterium infantis* (*B. infantis*) can repair the acute intestinal mucosal injury and maintain autoimmune tolerance in mice with IBD.

***Research motivation***

The specific mechanism of action of *B. infantis* in the treatment of IBD is unclear. Understanding this underlying mechanism will help in the treatment of IBD.

***Research objectives***

To explore if *B. infantis* can promote regulatory T cell Treg differentiation through the programmed cell death 1 (PD-1)/PD ligand (PD-L1) pathway to promote the expression of forkhead box protein 3 (Foxp3), interleukin (IL)-10 and transforming growth factor β (TGF-β) 1, and reduce the inflammatory response.

***Research methods***

We blocked the expression of PD-L1 in the intestine and performed western blotting and real-time qPCR to observe the effects of *B. infantis* on PD-1, Foxp3, IL-10, and TGF-β1. Flow cytometry was used to examine the changes in the differentiation of CD4+, CD25+, and Foxp3+ cells in the blood and spleen after blocking PD-L1.

***Research results***

PD-L1 inhibition reduced the promoting effects of *B. infantis* on intestinal PD-1, Foxp3, IL-10, and TGF-β1. The promoting effect of *B. infantis* on the differentiation of CD4+, CD25+, and Foxp3+ cells was also reduced.

***Research conclusions***

*B. infantis* mediates Foxp3 expression through the PD-1/PD-L1 pathway, thereby promoting Treg differentiation and improving IL-10 and TGF-β1 expression to reduce the immune and inflammatory response in IBD. *B. infantis* may act as a therapeutic agent for IBD.

***Research perspectives***

To explore the mechanism of action of *B. infantis* in the treatment of IBD at the cellular level. Further experiments are essential to determine whether *B. infantis* inhibits the immune response through the PD-1/PD-L1 pathway in the patients with IBD.

**ACKNOWLEDGEMENTS**

The authors thank Professor Liu DY for her guidance during the experiments.

**REFERENCES**

1 **Burisch J**, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, Andersen KW, Andersen V, Kaimakliotis IP, Fumery M, Gower-Rousseau C, Girardin G, Valpiani D, Goldis A, Brinar M, Čuković-Čavka S, Oksanen P, Collin P, Barros L, Magro F, Misra R, Arebi N, Eriksson C, Halfvarson J, Kievit HAL, Pedersen N, Kjeldsen J, Myers S, Sebastian S, Katsanos KH, Christodoulou DK, Midjord J, Nielsen KR, Kiudelis G, Kupcinskas L, Nikulina I, Belousova E, Schwartz D, Odes S, Salupere R, Carmona A, Pineda JR, Vegh Z, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. *J Gastroenterol Hepatol* 2019; **34**: 996-1003 [PMID: 30562421 DOI: 10.1111/jgh.14563]

2 **Olendzki B**, Bucci V, Cawley C, Maserati R, McManus M, Olednzki E, Madziar C, Chiang D, Ward DV, Pellish R, Foley C, Bhattarai S, McCormick BA, Maldonado-Contreras A. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study. *Gut Microbes* 2022; **14**: 2046244 [PMID: 35311458 DOI: 10.1080/19490976.2022.2046244]

3 **Lo Sasso G**, Phillips BW, Sewer A, Battey JND, Kondylis A, Talikka M, Titz B, Guedj E, Peric D, Bornand D, Dulize R, Merg C, Corciulo M, Ouadi S, Yanuar R, Tung CK, Ivanov NV, Peitsch MC, Hoeng J. The reduction of DSS-induced colitis severity in mice exposed to cigarette smoke is linked to immune modulation and microbial shifts. *Sci Rep* 2020; **10**: 3829 [PMID: 32123204 DOI: 10.1038/s41598-020-60175-3]

4 **Algethmi W**, Baumann C, Alnajjar W, Sroji A, Alsahafi M, Jawa H, Qari Y, Peyrin-Biroulet L, Saadah OI, Mosli M. Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia. *Eur J Gastroenterol Hepatol* 2020; **32**: 358-364 [PMID: 31851095 DOI: 10.1097/MEG.0000000000001619]

5 **Illiano P**, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. *FEBS J* 2020; **287**: 833-855 [PMID: 31955527 DOI: 10.1111/febs.15217]

6 **Lavelle A**, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 223-237 [PMID: 32076145 DOI: 10.1038/s41575-019-0258-z]

7 **Sartor RB**. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]

8 **Li J**, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. *Cancer Res* 2015; **75**: 508-518 [PMID: 25480946 DOI: 10.1158/0008-5472.CAN-14-1215]

9 **Pauken KE**, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, Wherry EJ. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* 2016; **354**: 1160-1165 [PMID: 27789795 DOI: 10.1126/science.aaf2807]

10 **Garcia-Bates TM**, Palma ML, Shen C, Gambotto A, Macatangay BJC, Ferris RL, Rinaldo CR, Mailliard RB. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. *J Virol* 2019; **93** [PMID: 30541848 DOI: 10.1128/JVI.02035-18]

11 **Zamani MR**, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: A growing relationship. *Cell Immunol* 2016; **310**: 27-41 [PMID: 27660198 DOI: 10.1016/j.cellimm.2016.09.009]

12 **Kuol N**, Stojanovska L, Nurgali K, Apostolopoulos V. PD-1/PD-L1 in disease. *Immunotherapy* 2018; **10**: 149-160 [PMID: 29260623 DOI: 10.2217/imt-2017-0120]

13 **Long Y**, Xia C, Sun Y, Ma Y, Xu L, Song Y, Liu C. Increased circulating PD-1hiCXCR5- peripheral helper T cells are associated with disease severity of active ulcerative colitis patients. *Immunol Lett* 2021; **233**: 2-10 [PMID: 33675861 DOI: 10.1016/j.imlet.2021.03.001]

14 **Li JY**, Yu M, Pal S, Tyagi AM, Dar H, Adams J, Weitzmann MN, Jones RM, Pacifici R. Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota. *J Clin Invest* 2020; **130**: 1767-1781 [PMID: 31917685 DOI: 10.1172/JCI133473]

15 **Hartwig T**, Zwicky P, Schreiner B, Yawalkar N, Cheng P, Navarini A, Dummer R, Flatz L, Conrad C, Schlapbach C, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. *Cell Rep* 2018; **25**: 3564-3572.e4 [PMID: 30590032 DOI: 10.1016/j.celrep.2018.12.012]

16 **Barbi J**, Pardoll D, Pan F. Treg functional stability and its responsiveness to the microenvironment. *Immunol Rev* 2014; **259**: 115-139 [PMID: 24712463 DOI: 10.1111/imr.12172]

17 **Vitale A**, Strisciuglio C, Vitale S, Santopaolo M, Bruzzese D, Micillo T, Scarpato E, Miele E, Staiano A, Troncone R, Matarese G, Gianfrani C. Increased frequency of regulatory T cells in pediatric inflammatory bowel disease at diagnosis: a compensative role? *Pediatr Res* 2020; **87**: 853-861 [PMID: 31715619 DOI: 10.1038/s41390-019-0662-7]

18 **O'Garra A**, Vieira P. Regulatory T cells and mechanisms of immune system control. *Nat Med* 2004; **10**: 801-805 [PMID: 15286781 DOI: 10.1038/nm0804-801]

19 **Maul J**, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. *Gastroenterology* 2005; **128**: 1868-1878 [PMID: 15940622 DOI: 10.1053/j.gastro.2005.03.043]

20 **Francisco LM**, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med* 2009; **206**: 3015-3029 [PMID: 20008522 DOI: 10.1084/jem.20090847]

21 **Ding Q**, Lu L, Zhou X, Zhou Y, Chou KY. Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. *J Leukoc Biol* 2011; **90**: 77-86 [PMID: 21498584 DOI: 10.1189/jlb.1210691]

22 **Zhou L**, Liu D, Xie Y, Yao X, Li Y. *Bifidobacterium infantis* Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease. *Gut Liver* 2019; **13**: 430-439 [PMID: 30600673 DOI: 10.5009/gnl18316]

23 **Chaudhary CL**, Gurung P, Jang S, Banskota S, Nam TG, Kim JA, Jeong BS. Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease. *J Enzyme Inhib Med Chem* 2020; **35**: 1-20 [PMID: 31619080 DOI: 10.1080/14756366.2019.1677637]

24 **Lee KH**, Ahn BS, Cha D, Jang WW, Choi E, Park S, Park JH, Oh J, Jung DE, Park H, Park JH, Suh Y, Jin D, Lee S, Jang YH, Yoon T, Park MK, Seong Y, Pyo J, Yang S, Kwon Y, Jung H, Lim CK, Hong JB, Park Y, Choi E, Shin JI, Kronbichler A. Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review. *Autoimmun Rev* 2020; **19**: 102469 [PMID: 31918027 DOI: 10.1016/j.autrev.2020.102469]

25 **Eichele DD**, Kharbanda KK. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. *World J Gastroenterol* 2017; **23**: 6016-6029 [PMID: 28970718 DOI: 10.3748/wjg.v23.i33.6016]

26 **Yan PG**, Li JN. Advances in the understanding of the intestinal micro-environment and inflammatory bowel disease. *Chin Med J (Engl)* 2020; **133**: 834-841 [PMID: 32106123 DOI: 10.1097/CM9.0000000000000718]

27 **Aden K**, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. *Gastroenterology* 2019; **157**: 1279-1292.e11 [PMID: 31326413 DOI: 10.1053/j.gastro.2019.07.025]

28 **Yan Y**, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman SV, Merlin D. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. *PLoS One* 2009; **4**: e6073 [PMID: 19562033 DOI: 10.1371/journal.pone.0006073]

29 **Hall LJ**, Faivre E, Quinlan A, Shanahan F, Nally K, Melgar S. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. *Dig Dis Sci* 2011; **56**: 79-89 [PMID: 20467900 DOI: 10.1007/s10620-010-1240-3]

30 **Fukata M**, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, Nast CC, Lechago J, Xu R, Naiki Y, Soliman A, Arditi M, Abreu MT. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G1055-G1065 [PMID: 15826931 DOI: 10.1152/ajpgi.00328.2004]

31 **Chen L**, Pai V, Levinson R, Sharpe AH, Freeman GJ, Braun J, Gordon LK. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. *Ocul Immunol Inflamm* 2009; **17**: 47-55 [PMID: 19294574 DOI: 10.1080/09273940802491884]

32 **Roosenboom B**, Horjus Talabur Horje CS, Smids C, Leeuwis JW, van Koolwijk E, Groenen MJM, Wahab PJ, van Lochem EG. Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies. *Scand J Gastroenterol* 2021; **56**: 671-679 [PMID: 33779456 DOI: 10.1080/00365521.2021.1906316]

33 **Bodhankar S**, Galipeau D, Vandenbark AA, Offner H. PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. *J Clin Cell Immunol* 2013; **4**: 143 [PMID: 24009988 DOI: 10.4172/2155-9899.1000143]

34 **Gianchecchi E**, Fierabracci A. Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. *Front Immunol* 2018; **9**: 2374 [PMID: 30386337 DOI: 10.3389/fimmu.2018.02374]

35 **O'Shaughnessy MJ**, Murray KS, La Rosa SP, Budhu S, Merghoub T, Somma A, Monette S, Kim K, Corradi RB, Scherz A, Coleman JA. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. *Clin Cancer Res* 2018; **24**: 592-599 [PMID: 28954788 DOI: 10.1158/1078-0432.CCR-17-0186]

36 **Lo YC**, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. *Am J Clin Pathol* 2021; **156**: 214-228 [PMID: 33555016 DOI: 10.1093/ajcp/aqaa217]

37 **Elian SD**, Souza EL, Vieira AT, Teixeira MM, Arantes RM, Nicoli JR, Martins FS. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. *Benef Microbes* 2015; **6**: 277-286 [PMID: 25391346 DOI: 10.3920/BM2014.0070]

38 **Li Hui,** Gong Yi, Li Yan. Clinical efficacy of mesalazine combined with Clostridium butyricum in the treatment of active mild to moderate ulcerative colitis. Shiyong Yaowu Yu Linchuang 2016; 19: 1389-1393 [DOI: 10.14053/j.cnki.ppcr.201611017]

39 **Mi H**, Dong Y, Zhang B, Wang H, Peter CCK, Gao P, Fu H, Gao Y. Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats. *Cell Physiol Biochem* 2017; **42**: 2330-2341 [PMID: 28848081 DOI: 10.1159/000480005]

40 **Fu L**, Song J, Wang C, Fu S, Wang Y. *Bifidobacterium infantis* Potentially Alleviates Shrimp Tropomyosin-Induced Allergy by Tolerogenic Dendritic Cell-Dependent Induction of Regulatory T Cells and Alterations in Gut Microbiota. *Front Immunol* 2017; **8**: 1536 [PMID: 29176981 DOI: 10.3389/fimmu.2017.01536]

41 **Bozkurt HS,** Kara B. A new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan application. Eur J Inflamm 2020; 18: 1-7 [DOI:10.1177/2058739220942626]

42 **Zuo T**, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. *Front Microbiol* 2018; **9**: 2247 [PMID: 30319571 DOI: 10.3389/fmicb.2018.02247]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board at Shengjing Hospital of China Medical University.

**Institutional animal care and use committee statement:** All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals, No. 2017PS353K.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 6, 2021

**First decision:** January 8, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Bozkurt HS, Turkey; Rodrigues AT, Brazil; Serban ED, Romania **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**

**Figure Legends**





**Figure 1 The effects of blocking programmed cell death ligand.** A: Expression of programmed cell death 1 (PD-1) protein; B: Statistical chart showing the differences in PD-1 protein expression; C: Statistical map showing the differences in PD-1 mRNA expression; D: Western blot showing forkhead box protein 3 protein (Foxp3) expression; E: Statistical chart showing the differences in Foxp3 expression; F: Statistical map showing the differences in Foxp3 mRNA levels. Data are presented as mean ± SD, and comparisons between groups were analyzed by one-way analysis of variance. Statistical significance was set as *P* < 0.05. PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; DSS: Dextran sulfate sodium; *B. infantis*: *Bifidobacterium infantis*; Foxp3: Forkhead box protein 3.



**Figure 2 Effects of *Bifidobacterium infantis* and programmed cell death ligand inhibition on the proportion of CD4+, CD25+, and forkhead box protein 3+ cells in the blood.** A: The strategy of CD4+, CD25+, and forkhead box protein (Foxp) 3+ cells; B-F: Flow cytometry results for the control group (B), the DSS model group (C), the DSS + *B. infantis* group (D), the DSS + *B. infantis* + anti-PD-L1 group (E), the DSS + anti-PD-L1 group (F); G: Statistical chart of the numbers of CD4+, CD25+, and Foxp3+ cells. Data are presented as mean ± SD, and the comparisons among each group were analyzed by one-way analysis of variance. Statistical significance was set as *P* < 0.05. PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand; DSS: Dextran sulfate sodium; *B. infantis: Bifidobacterium infantis*; Foxp3+: Forkhead box protein 3+; CD: Cluster of differentiation; SSC: Side scatter; FSC: Forward scatter; FL: Fluorescence; APC: Allophycocyanin; FITC: Fluorescein isothiocyanate; H: Height.



**Figure 3 Effects of *Bifidobacterium infantis* and programmed cell death ligand inhibition on the proportion of splenic CD4+, CD25+, and forkhead box protein 3+ cells.** A: The strategy of CD4+, CD25+, and forkhead box protein (Foxp) 3+ cells; B-F: Flow cytometry results for the the control group (B), the DSS model group (C), the DSS + *B. infantis* group (D), the DSS + *B. infantis* + anti-PD-L1 group (E); and the DSS + anti-PD-L1 group (F); G: Statistical chart of the numbers of CD4+, CD25+, and Foxp3+ cells. Data are presented as mean ± SD, and the comparisons among each group were analyzed by one-way analysis of variance. Statistical significance was set as *P* < 0.05. PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand; DSS: Dextran sulfate sodium; *B. infantis*: *Bifidobacterium infantis*; Foxp3+: Forkhead box protein 3+; CD: Cluster of differentiation; SSC: Side scatter; FSC: Forward scatter; FL: Fluorescence; APC: Allophycocyanin; FITC: Fluorescein isothiocyanate; H: Height.



**Figure 4 Effects of programmed cell death ligand inhibition on the expression of interleukin-10 and transforming growth factor β 1.** A: Western blot showing interleukin (IL)-10 and transforming growth factor β (TGF-β) 1 protein expression; B-E: Statistical maps of the differences in IL-10 protein expression (B), TGF-β1 protein expression (C), IL-10 mRNA expression (D), and TGF-β1 expression (E). Data are presented as mean ± SD, and the comparisons among each group were analyzed by one-way analysis of variance. Statistical significance was set as *P* < 0.05. PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand; DSS: Dextran sulfate sodium; *B. infantis: Bifidobacterium infantis*; IL: Interleukin; TGF-β: Transforming growth factor β; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; mRNA: Messenger ribonucleic acid.

**Table 1 Preparation of reverse transcription system**

|  |  |
| --- | --- |
| **Reagent** | **Dose (****µL)** |
| 5 × prime script buffer | 4 |
| Prime sript RT enzyme mix | 1 |
| RT primer xix | 1 |
| ddH2O | 4 |

RT: Real time; dd: Double distilled.